Kunisawa Susumu, Kobayashi Daisuke, Lee Jason, Otsubo Tetsuya, Ikai Hiroshi, Yokota Chiaki, Minematsu Kazuo, Imanaka Yuichi
Department of Healthcare Economics and Quality Management, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.
J Stroke Cerebrovasc Dis. 2014 Apr;23(4):724-31. doi: 10.1016/j.jstrokecerebrovasdis.2013.06.033. Epub 2013 Jul 30.
The use of intravenous tissue plasminogen activator (t-PA) can be an effective treatment for acute ischemic stroke if administered promptly. Despite its clinical effectiveness, overall use in Japan remains low, and regional variations have been reported. Factors such as ambulance utilization and geographical distance from patients' residences to hospitals may influence t-PA administration rates. The aim of this study is to identify factors associated with the administration of t-PA for acute ischemic stroke while adjusting for casemix using a large-scale administrative database in Japan.
We analyzed acute ischemic stroke patients admitted to acute care hospitals between July 2010 and March 2011 using a nationwide database. A logistic regression model was used to analyze the factors influencing t-PA administration. Candidate factors included patient gender, age, stroke severity, direct distance between each patient's residence and admitting hospital, and ambulance utilization.
Of the 10,615 ischemic stroke patients from 89 hospitals analyzed, 557 (5.2%) received t-PA treatment. Patients aged 75 years and older were found to be associated with decreased t-PA administration. In contrast, severe stroke and ambulance utilization were associated with increased t-PA administration. Distance was not significantly associated with the use of t-PA.
Our findings suggest that ambulance utilization is an important factor for improving the likelihood of t-PA administration in patients with stroke and may underline a need for educational programs to the general public that promote the use of ambulances for suspected stroke patients.
如果能及时给药,静脉注射组织型纤溶酶原激活剂(t-PA)可有效治疗急性缺血性卒中。尽管其具有临床疗效,但在日本的总体使用率仍然较低,且存在地区差异的报道。诸如救护车使用率以及患者住所与医院的地理距离等因素可能会影响t-PA的给药率。本研究的目的是利用日本的一个大规模行政数据库,在调整病例组合的同时,确定与急性缺血性卒中t-PA给药相关的因素。
我们使用一个全国性数据库分析了2010年7月至2011年3月期间入住急症医院的急性缺血性卒中患者。采用逻辑回归模型分析影响t-PA给药的因素。候选因素包括患者性别、年龄、卒中严重程度、每位患者住所与收治医院之间的直线距离以及救护车使用率。
在分析的来自89家医院的10615例缺血性卒中患者中,557例(5.2%)接受了t-PA治疗。发现75岁及以上的患者t-PA给药率降低。相比之下,严重卒中及救护车使用率与t-PA给药率增加有关。距离与t-PA的使用无显著关联。
我们的研究结果表明,救护车使用率是提高卒中患者t-PA给药可能性的一个重要因素,可能凸显了对公众开展教育项目以促进疑似卒中患者使用救护车的必要性。